Voluntis

What Voluntis does

Voluntis is a France-based, public digital health company (EPA: ALVTX) founded in 2001 and now operating as Aptar Digital Health, a division of Aptar Pharma. The company builds a certified, cloud-native digital health platform that delivers companion apps, connected drug-delivery devices, Software as a Medical Device (SaMD), digital Patient Support Programs, and Study & Data Services to global pharmaceutical and biotech partners across 120 countries. Its portfolio includes proprietary consumer-facing apps (Migraine Buddy, Esme for multiple sclerosis, Allergy Buddy), connected drug-delivery hardware such as the FDA 510(k)-cleared HeroTracker Sense, and AI-powered screening algorithms licensed to AstraZeneca.

The platform is underpinned by ISO 13485, ISO 27001, MDSAP, HIPAA, and GDPR certifications and is designed for integration with EHRs, sensors, hubs, and patient support workflows. Voluntis monetizes through multi-year enterprise SaaS subscriptions with pharma and biotech partners, connected device sales, IP licensing (e.g., AstraZeneca AI screening algorithms), and professional services for virtual clinical studies and real-world evidence generation. Its named enterprise customers include AbbVie, Bristol Myers Squibb, Chiesi, Eisai, Novartis, Sanofi, AstraZeneca, and Stallergenes Greer, with partnerships extending to medical device manufacturers (Enable Injections), consumer health products (Oura), and healthcare providers (Moffitt Cancer Center).

The business model is enterprise B2B sales-led, with co-developed and tailored solutions per pharma partner, supported by channel partnerships and event-driven demand generation at conferences such as CMSC and HLTH Europe. With 51–100 employees and operations spanning 120 countries, 17 clinical studies supported, and 15+ regulatory approvals, Voluntis operates as a focused mid-sized regulated digital health unit leveraging Aptar Pharma's global drug-delivery infrastructure.

Name

Voluntis

Legal name

Voluntis

Website

https://voluntis.com

Company type

Private

Founded year

2001

Operating status

Operating

Headcount range

51–100 employees

Short description

Voluntis, operating as Aptar Digital Health (a division of Aptar Pharma), provides a certified digital health platform of companion apps, connected drug-delivery devices, SaMD, and real-world evidence services to global pharmaceutical and biotech partners across 120 countries.

Ownership category

akta.pro rank

Product category

Digital Health Software

NAICS

Software Publishers (51321)

SIC

Services-Prepackaged Software (7372), Surgical & Medical Instruments & Apparatus (3841)

akta.pro primary industry

Therapeutic Companion Apps (Drug-Device-Digital Combination) (HLACANAH)

akta.pro secondary industries

Medication Adherence & Smart Drug Delivery (Connected Inhalers, Pens, Pill Dispensers) (HLACAPAH), DTx/SaMD Evidence, Outcomes & Real-World Data (RWE) Platforms (HLACANAM), DTx/SaMD Deployment, Integration & Reimbursement Enablement (HLACANAO)

Keywords

• Digital health software
• Companion medical apps
• Connected drug delivery
• Patient support platforms
• Real world evidence

Headquarters

HQ city

Suresnes

HQ country

France

HQ region

Europe

Offices2 records

Markets served

GTM type

B2B

Offering type

Software

Cost components

Technology or R&D, Personnel, Operations, Marketing or Sales, Supply Chain

Revenue model

1. B2B Enterprise SaaS for Pharma: Subscription/contract-based revenue from pharmaceutical and biotech partners licensing the digital health platform, companion apps, connected devices, and SaMD solutions. Long-term enterprise contracts with global life sciences partners.
2. Connected Drug-Delivery Device Sales: Revenue from connected drug-delivery device solutions (e.g., HeroTracker Sense) integrated with patient companion apps to capture usage and adherence data.
3. Licensing Agreements: Licensing revenue from agreements such as the AstraZeneca deal to develop AI-Powered Screening Algorithms, monetizing proprietary technology through IP licensing.
4. Study & Data / Real-World Evidence Services: Professional services revenue from running virtual clinical studies, post-marketing studies, and generating real-world evidence for pharma brand teams using digital capabilities.

Pricing tiers

Go-to-market motion3 records

Distribution channels4 records

Marketing channels6 records

Core offering

Voluntis develops regulated digital health software that combines companion mobile apps, connected drug-delivery devices, and clinical study and real-world evidence services. The company partners with pharmaceutical and biotech manufacturers to deliver patient support programs, disease management solutions, and software as a medical device (SaMD) across 120 countries.

Product overview

Aptar Digital Health — the division of Aptar Pharma that houses Voluntis — operates as a platform-plus-modules architecture delivered to global pharma and biotech partners across 120 countries. The certified, cloud-native platform underpins a portfolio of regulated companion apps (including Migraine Buddy®, Esme, and Allergy Buddy), connected drug-delivery devices (such as the FDA 510(k)-cleared HeroTracker® Sense), Software as a Medical Device (SaMD) modules, Digital PSPs, a Disease Management Platform, and Study & Data Services. The named apps (Migraine Buddy, Esme, Allergy Buddy) and HeroTracker® Sense are concrete user- or patient-facing offerings built on top of the core platform, while SaMD, Digital PSP, Disease Management Platform, and Study Support are configurable modules/engagement models used to tailor solutions to specific drugs, indications, and patient journeys.

Differentiator

Problem solved

Functional benefit

Products and services

• HeroTracker Sense

Quantifiable outcome

• Operates across 120 countries globally
• +3 more outcomes

Named customers10 records

Segments3 records

Ideal customer profiles3 records

Technology focussed Yes

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

Integration2 records

AI capability5 records

Feature8 records

Partnerships

Twelve partnerships are on record, tiered core and flagship.

• Enable InjectionscoreStrategic or Co-development Partner · 9 April 2026Partnership to develop the enFuse® Companion Digital Solution, combining Enable Injections' enFuse wearable drug-delivery platform with Aptar Digital Health's digital health expertise to enhance patient experience during self-administration. Announced April 9, 2026.
• ŌURAcoreTechnology or Integration · 7 January 2026Collaboration to advance migraine insights by connecting Migraine Buddy® with the Oura Ring, enabling users to correlate physiological data with migraine symptoms, triggers, and treatments. Announced January 7, 2026.
• AstraZenecaflagshipOEM/ Whitelabel/ Licensing Partner · 22 May 2025Licensing agreement to develop AI-Powered Screening Algorithms, leveraging Aptar Digital Health's AI capabilities under license for AstraZeneca's therapeutic areas. Announced May 22, 2025.
• Aptar PharmaflagshipStrategic or Co-development PartnerOperates as "A Division of Aptar Pharma", benefiting from parent company's drug delivery expertise, global pharma relationships, and operational scale.
• AbbViecoreStrategic or Co-development PartnerGlobal pharmaceutical partner leveraging the digital health platform; listed among "trusted partner of leading pharmaceutical companies at a global level".
• Bristol Myers SquibbcoreStrategic or Co-development PartnerGlobal pharmaceutical partner leveraging the digital health platform; listed as a trusted partner at a global level.
• ChiesicoreStrategic or Co-development PartnerGlobal pharmaceutical partner leveraging the digital health platform; listed as a trusted partner.
• EisaicoreStrategic or Co-development PartnerGlobal pharmaceutical partner leveraging the digital health platform; listed as a trusted partner.
• NovartisflagshipStrategic or Co-development PartnerGlobal pharmaceutical partner leveraging the digital health platform; listed as a trusted partner of leading pharmaceutical companies at a global level.
• SanofiflagshipStrategic or Co-development PartnerGlobal pharmaceutical partner leveraging the digital health platform; listed as a trusted partner at a global level.
• Stallergenes GreercoreStrategic or Co-development PartnerPharmaceutical partner in respiratory/allergy therapeutic area leveraging the digital health platform.
• Moffitt Cancer CentercoreImplementation/ SI/ Consulting PartnerHealthcare/cancer center partner supporting oncology-related digital health initiatives; logo featured on the website partner wall.

Scale indicators4 records

Recent moves6 records

Expansion highlights6 records

Direct peers

• BrightInsight: BrightInsight operates a regulated digital health platform purpose-built for pharma and biopharma, offering SaMD, companion apps, and connected device solutions. It is the closest direct peer to Voluntis in terms of regulated platform positioning and pharma/biotech GTM motion.
• S3 Connected Health: S3 Connected Health provides regulated digital health platforms and connected drug-delivery companion apps for global pharma. It directly competes with Voluntis in the pharma digital companion and connected-device integration space.
• Biofourmis: Biofourmis builds digital therapeutics and AI-enabled remote monitoring platforms that integrate with pharma drug programs. It is a direct peer in the regulated SaMD and pharma partnership category.
• Click Therapeutics: Click Therapeutics develops prescription digital therapeutics in partnership with major pharma sponsors (e.g., Otsuka). It is a direct peer in the prescription DTx and pharma co-development model.
• Propeller Health: Propeller Health (now part of ResMed) offers connected inhaler sensors and companion apps for respiratory therapy, mirroring Voluntis's HeroTracker Sense and respiratory therapeutic area focus.
• mySugr: mySugr (acquired by Roche) provides a chronic disease companion app ecosystem integrated with pharma and device partners. It is comparable in patient-facing companion app model and pharma partnership monetization.
• Medisafe: Medisafe offers a medication adherence companion platform with pharma integrations. It directly competes with Voluntis in the medication adherence and patient engagement category.
• WellDoc: WellDoc develops FDA-cleared digital therapeutics, notably for diabetes, in partnership with pharma and payers. It is a direct peer in the regulated SaMD/DTx and pharma partnership model.
• AdhereTech: AdhereTech builds connected medication adherence devices and supporting software for pharma. It is a direct peer in connected drug-delivery devices with pharma partnerships.
• Huma: Huma (formerly Huma Therapeutics) operates a regulated digital health platform for hospitals, pharma, and research, including companion apps and SaMD modules. It is comparable as a regulated digital health platform with pharma partners.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat6 records

Key risks6 records

Key highlights7 records

Customer concentration

• Xx.com/Voluntis
• Facebookfacebook.com/qualcomm
• LinkedInlinkedin.com/company/voluntis

Compliance5 records

Revenue estimate

Valuation estimate

Number of profiles

Profiles11 records

Funding overview

Funding rounds4 records

Investors8 records

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Voluntis